How GLP-1 weight-loss drugs affect saliva and teeth
Part of Hormones & metabolism, Mouth & dental clinical trials.
This study looks at how weight-loss medications (GLP-1 drugs) might affect your saliva and teeth. If you're starting one of these medications, the study will check your mouth health before you start and again after 3 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your body mass index (BMI, a measure of body fat based on height and weight) must be 27 or higher.
- A doctor specializing in hormones (endocrinologist) must decide that you should start a GLP-1 medication like semaglutide or tirzepatide for weight management.
- You must not have taken any GLP-1 medication before.
- You must be willing to attend both the first visit and a follow-up visit about 3 months later.
- You cannot have certain health conditions that affect your mouth or saliva, like Sjögren syndrome, chronic kidney disease, or severe tooth decay that needs treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how GLP-1 receptor agonist drugs (used for weight loss) affect muscle mass and strength in people with obesity who do not have diabetes. It may help understand if these medications impact muscle health.
This trial looks at how GLP-1 receptor agonist medications (like liraglutide or semaglutide) affect bone health in adolescents and young adults with obesity. It aims to understand if these weight loss drugs have any impact on bone density and metabolism.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
This study is for people who have lost weight using GLP-1 injections (like semaglutide or tirzepatide) and are thinking about stopping them. It tests whether switching to an oral weight-loss medication can help you keep the weight off.
This study tests a new oral medication called ACCG-2671 to see how safe it is and how your body handles it. It's an early-stage trial, so the main focus is on safety and tolerability. The study has different parts: one for people with normal weight and one for people with higher weight who are already taking a GLP-1 injection for weight loss.
This study looks at how a class of drugs called GLP-1 receptor agonists, used for type 2 diabetes and obesity, affect your saliva and oral health. If you are new to this medication, you may help us understand its benefits and risks for your mouth.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.